Modality
Radioligand
MOA
CD3xCD20
Target
VEGF
Pathway
Sphingolipid
SchizophreniaWet AMD
Development Pipeline
Preclinical
~Jul 2016
→ ~Oct 2017
Phase 1
~Jan 2018
→ ~Apr 2019
Phase 2
Jul 2019
→ Oct 2030
Phase 2Current
NCT06735307
1,126 pts·Schizophrenia
2019-07→2030-10·Terminated
1,126 total pts1 indication
Phase 3
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (1)
2030-10-214.6y awayPh3 Readout· Schizophrenia
Trial Timeline
Q3Q42020Q2Q3Q42021Q2Q3Q42022Q2Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2Q3Q42028Q2Q3Q42029Q2Q3Q42030Q2Q3Q4
P2/3
Termina…
Catalysts
Ph3 Readout
2030-10-21 · 4.6y away
Schizophrenia
Terminated|StartCompletionToday
Trials (1)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT06735307 | Phase 2/3 | Schizophrenia | Terminated | 1126 | EFS |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| LLY-1184 | Eli Lilly | NDA/BLA | C5 | |
| Zanuderotide | Novartis | Phase 1/2 | VEGF | |
| NVO-1361 | Novo Nordisk | Phase 3 | CD38 | |
| Zorizanubrutinib | Novo Nordisk | Phase 1 | BTK | |
| TAK-8730 | Takeda | Phase 2 | VEGF | |
| Pexamavacamten | Daiichi Sankyo | NDA/BLA | TIGIT | |
| GIL-2011 | Gilead Sciences | Preclinical | VEGF | |
| Bemazumab | Regeneron | Phase 1 | VEGF | |
| Pemicapivasertib | Legend Biotech | Phase 3 | VEGF | |
| Sematapinarof | Legend Biotech | NDA/BLA | VEGF |